Search results
Found 16132 matches for
The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.
Psychiatry Annual Report 2023
Psychiatry annual report 2-23 - read a fully accessible version of the text below
Psychosocial assessment following self-harm
Psychosocial assessment following self-harm: a clinician's guide
PSYCHOSOCIAL assessment following self-harm Clinician's guide.pdf (916 KB)